Florida Surgeon General Dr. Joseph A. Ladapo announced new guidance on messenger RNA (mRNA) vaccines on Oct. 7, specifically recommending against administering mRNA COVID-19 vaccines to males aged 18 to 39.
Messenger RNA is the technology utilized by both the Pfizer and Moderna COVID-19 vaccines, the most administered vaccines in the United States and a number of other countries.
"Non-mRNA vaccines were not found to have these increased risks," the Florida Department of Health noted.
Given the high level of global immunity to COVID-19, the benefit of vaccination with mRNA vaccines "is likely outweighed by this abnormally high risk of cardiac-related death among men in this age group," the department said.
"As such, the State Surgeon General recommends against males aged 18 to 39 from receiving mRNA COVID-19 vaccines," it said. "Those with preexisting cardiac conditions, such as myocarditis and pericarditis, should take particular caution when making this decision."
"Far less attention has been paid to safety and the concerns of many individuals have been dismissed—these are important findings that should be communicated to Floridians," Ladapo said in a statement, referring to the analysis.
Statewide AnalysisThe analysis from the Florida Health Department that informed Ladapo's latest recommendation had sought to "evaluate the risks of all-cause and cardiac-related mortality following COVID-19 vaccination."
Residents in Florida aged 18 years or older who died within 25 weeks of having received a COVID-19 vaccine, since the start of the vaccination roll-out in the state—Dec. 15, 2020—were included. The study end date was June 1, 2022.
People were excluded from the study if they had a documented COVID-19 infection, had a COVID-19-associated death, had received a COVID-19 vaccine booster, or had received their last COVID-19 vaccine after Dec. 8, 2021. The last criterion was put in place to make sure that each person was followed up after 25 weeks.
The study found that COVID-19 vaccination "was not associated with an elevated risk for all-cause mortality," but "was associated with a modestly increased risk for cardiac-related mortality 28 days following vaccination."
"Results from the stratified analysis for cardiac-related death following vaccination suggests mRNA vaccination may be driving the increased risk in males, especially among males aged 18–39," according to the analysis.
It also noted that the risk for both all-cause and cardiac-related deaths was "substantially higher 28 days following COVID-19 infection."
As such, the study concluded that people should weigh the risk associated with mRNA vaccination with the risk associated with COVID-19 infection.
The analysis was a self-controlled case series (SCCS), which is a study design originally developed to evaluate vaccine safety, the department stated. The SCCS method uses individuals as their own control, such that comparisons are made within individuals.
The U.S. Food and Drug Administration's authorization of the Pfizer-BioNTech and Moderna COVID-19 vaccines for emergency use in 2020 marked the first time it did so for vaccines that use mRNA technology.
The primary regimens of the vaccines, which are two doses administrated several weeks apart, were insufficient to protect against infection and showed waning efficacy in protecting against hospitalization amid newly-emerging variants. This prompted the governments of many countries to recommend boosters and subsequent boosters throughout the COVID-19 pandemic.